Yubo Xie

Dr. Yubo Xie


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
TLTianxiao Liu
Tianxiao Liu
TLTing Lai
Ting Lai
JCJing Chen
Jing Chen
YLYizhi Lu
Yizhi Lu
FHFang He
Fang He
YXYubo Xie
Yubo Xie
Background: The stability of hemodynamics during anesthesia induction in patients undergoing valve replacement surgery is particularly important. Remimazolam is a new type of benzodiazepine drug, with supposed advantages of rapid induction, rapid recovery, stable hemodynamics, and mild respiratory inhibition.Aim: To evaluate the effect of remimazolam anesthesia induction on hemodynamics in patients undergoing valve replacement surgery.Methods: This randomized, double‐blind, controlled trial enrolled consecutive patients undergoing mitral valve replacement (MVR)/aortic valve replacement (AVR)/double‐valve replacement (DVR) surgery on cardiopulmonary bypass (CPB). The study was conducted according to the Consolidated Standards of Reporting Trials statement. Participants were randomly assigned to receive either remimazolam or propofol induction of 30 patients each. All patients, data collectors, and data analyzers were blinded to the group allocation. The primary outcomes were the fluctuations in hemodynamic parameters (the difference of maximum or minimum heart rate to baseline, ▲HR, the difference of maximum or minimum mean arterial pressure to baseline, ▲MAP), the occurrence of cardiovascular events (hypotension, severe bradycardia), and the cumulative norepinephrine doses used per patient, averaged per group during induction. The secondary outcomes were hemodynamic parameters (heart rate, HR, mean arterial pressure, MAP, bispectral index, BIS, plasma lactic acid, Lac, and blood glucose, Glu values).Results: A total of 60 patients with heart valve replacement were included in the final analysis, with 30 patients in each group. The ▲MAP was significantly lower in the remimazolam group than in the propofol group during induction (p < .05). The incidences of hypotension and the cumulative norepinephrine doses used per patient, averaged per group during induction were significantly lower in the remimazolam group than in the propofol group (p < .05).Conclusion: Remimazolam may be safe and effective for induction and may as an alternative to propofol during anesthesia induction in patients undergoing valve replacement surgery.

1 February 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MSMin Shi
Min Shi
JCJing Chen
Jing Chen
TLTianxiao Liu
Tianxiao Liu
WDWeixin Dai
Weixin Dai
ZZZhan Zhou
Zhan Zhou
YXYubo Xie
Yubo Xie
Introduction: Remimazolam is a novel benzodiazepine γ-aminobutyric acid A (GABAa) receptor agonist used for sedation and the induction as well as maintenance of general anesthesia. Previous research proved that anesthetic agents acting on GABAa receptor, such as thiopentone, propofol and midazolam, have protective actions for cerebral ischemia/reperfusion (I/R) injury. We here probed into remimazolam for its protective effect and potential mechanism of action against cerebral I/R injury. Material and Methods: A rat model of middle cerebral artery occlusion (MCAO) with focal transient cerebral I/R injury was established and was given tail vein injection of gradient remimazolam (5, 10, 20 mg/kg) after 2 h of ischemia. Following 24 h of reperfusion, neurological function, brain infarct volume, morphology of cerebral cortical neurons, and expressions of corticocerebral NLRP3, ASC, caspase-1, GSDMD, IL-1β and IL-18 were evaluated. Results: The results showed that remimazolam could effectively improve the neurological dysfunction, reduce the infarct volume and alleviate the damage of cortical neurons after I/R injury. Notably, the expression of NLRP3 inflammasome pathway was down-regulated, suggesting that remimazolam exerted protective actions on I/R injury by suppressing pyroptosis with decreased expression and release of inflammatory factors, and the involvement of the NLRP3 inflammasome pathway might be the core during that process. Overall, our results indicate that NLRP3 inflammation is a promising target. Conclusion: Based on this mechanism, remimazolam may be one of the ideal anesthetic drugs for patients with ischemic stroke.

1 January 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
GHGuodong He
Guodong He
GHGuoliang He
Guoliang He
RZRiyong Zhou
Riyong Zhou
ZPZhibing Pi
Zhibing Pi
TZTianqi Zhu
Tianqi Zhu
YXYubo Xie
Yubo Xie

1 July 2018 in Brain Research
Verified
Journal Article
Closed access
YZYu Zhong
Yu Zhong
JCJing Chen
Jing Chen
LLLi Li
Li Li
YQYi Qin
Yi Qin
YWYi Wei
Yi Wei
YXYubo Xie
Yubo Xie

29 November 2023 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
STSiyou Tan
Siyou Tan
WCWenyan Chen
Wenyan Chen
GKGaoyin Kong
Gaoyin Kong
LWLai Wei
Lai Wei
YXYubo Xie
Yubo Xie
Cognitive impairments, such as learning and memory deficits, may occur in susceptible populations including the elderly and patients who are chronically ill or have experienced stressful events, including surgery, infection, and trauma. Accumulating lines of evidence suggested that peripheral inflammation featured by the recruitment of peripheral immune cells and the release of pro-inflammatory cytokines may be activated during aging and these conditions, participating in peripheral immune system-brain communication. Lots of progress has been achieved in deciphering the core bridging mechanism connecting peripheral inflammation and cognitive impairments, which may be helpful in developing early diagnosis, prognosis evaluation, and prevention methods based on peripheral blood circulation system sampling and intervention. In this review, we summarized the evolving evidence on the prevalence of peripheral inflammation-associated neurocognitive impairments and discussed the research advances in the underlying mechanisms. We also highlighted the prevention and treatment strategies against peripheral inflammation-associated cognitive dysfunction.

27 October 2016 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
GHGuodong He
Guodong He
CFChen Feng
Chen Feng
RVRajamanickam Vinothkumar
Rajamanickam Vinothkumar
WCWeiqian Chen
Weiqian Chen
XDXuanxuan Dai
Xuanxuan Dai
WWWei Wu
Wei Wu